Last updated on June 2019

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

---

Brief description of study

The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite receiving maximally-tolerated LMT. Persistent hypercholesterolemia is defined as LDL-C 70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C 100 mg/dL (2.59 mmol/L) for those patients without clinical ASCVD.